Jonathan Slonin - 17 Aug 2026 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Reporting relationship: Chief Medical Officer
Issuer ticker: PCRX
Reported as of: 17 Aug 2026
Net transaction value: -$70,619
SEC form: 4
Accepted by SEC: 18 Aug 2026, 17:21:16 UTC
Prior SEC filing: 05 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Kristen Williams, Attorney-in-Fact

Key filing fact

Jonathan Slonin filed Form 4 for Pacira BioSciences, Inc. (PCRX) on 18 Aug 2026.

Key facts

This page summarizes Jonathan Slonin's Form 4 filing for Pacira BioSciences, Inc. (PCRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 Aug 2026, 17:21.

Change

Previous filing in this sequence was filed on 05 Jun 2026.
Current net transaction value: -$70,619.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001875723 Primary reporting owner

SLONIN JONATHAN

Relationship: Chief Medical Officer
Address: C/O PACIRA BIOSCIENCES, INC., 2000 SIERRA POINT PARKWAY, SUITE 900, BRISBANE
Signature: /s/ Kristen Williams, Attorney-in-Fact
Signature date: 18 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PCRX transaction

Common Stock

Sale

Transaction value: $70,619
Shares: -3,040
Change %: -1.4%
Price: $23.23
Shares after: 216,384
Date: 17 Aug 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on August 12, 2025.

Footnote F2

Includes 511.471 shares of common stock acquired under the issuer's employee stock purchase plan in June 2026.